Results 241 to 250 of about 100,614 (290)

Staged approach to overcome hyperbilirubinemia: tailored chemotherapy in liver metastases-a case report. [PDF]

J Gastrointest Oncol
Chamseddine S, Choucair K, Saif MW.
europepmc   +1 more source

Harnessing the power of cancer-associated fibroblasts to revolutionize pancreatic cancer treatment. [PDF]

Cancer Biol Med
Shen J, Wu R, Yin T, Wang Q, Nie L.
europepmc   +1 more source

The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability. [PDF]

Cell Death Dis
Zhang W, Liu R, Hu J, Wan S, Zou Y, Che T, Zhang J, Chen L, Peng X.   +8 more
europepmc   +1 more source

Functionalized MoS₂ nanosheets as high-affinity nanocarriers for gemcitabine: a molecular simulation study. [PDF]

Sci Rep
Najafi F, Farzad F.
europepmc   +1 more source

Derazantinib enhances gemcitabine efficacy in PDAC by attenuating the NF-κB and MAPK pathways to suppress MUC5AC expression. [PDF]

Med Oncol
Ye W, Huang Y, Hong L, Ma Y, Huang J, Xu F, Han F, Qiu Y, Zou Z, Zhang Y, Li X.   +10 more
europepmc   +1 more source

Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical Trial.

JAMA Netw Open
Jeong H, Yoo C, Kim I, Kang JH, Jeong JH, Park K, Oh SB, Park I, Sym SJ, Cheon J, Ryu H, Hwang JE, Lee JS, Ryoo BY, Kim KP.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Gemcitabine

Reactions Weekly, 2002
Ines Mader, Patrizia E. Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, Sabine M. Wassertheurer   +5 more
  +5 more sources

Gemcitabine

Reactions Weekly, 2021
openaire   +2 more sources

Gemcitabine

Reactions Weekly, 2011
  +4 more sources